Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$417.86 USD
+3.85 (0.93%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $417.84 -0.02 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$417.86 USD
+3.85 (0.93%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $417.84 -0.02 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
B Value B Growth C Momentum B VGM
Zacks News
Zacks Industry Outlook Highlights Elevance Health, Cencora and ICON
by Zacks Equity Research
Elevance Health, Cencora and ICON are part of the Zacks Industry Outlook article.
3 Medical Services Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and ICLR are set to gain the most. However, staffing shortages continue to disrupt the growth trend.
Brokers Suggest Investing in Elevance Health (ELV): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Elevance Health (ELV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Elevance Health (ELV) Bolsters CarelonRx With Paragon Buyout
by Zacks Equity Research
The infusion services from Paragon Healthcare are expected to complement Elevance Health's (ELV) suite of pharmacy services.
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
by Zacks Equity Research
Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.
Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio
by Zacks Equity Research
Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.
ELV or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Elevance Health (ELV) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Elevance Health (ELV) stood at $498.35, denoting a -1.19% change from the preceding trading day.
BD (BDX) Initiates IDE Study to Aid Treatment of Artery Disease
by Zacks Equity Research
BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.
Philips (PHG), SyntheticMR Unite to Aid Brain Diagnosing Space
by Zacks Equity Research
Philips (PHG) and SyntheticMR collaborate to launch of Smart Quant Neuro 3D, which is likely to boost the brain diagnosing field by providing automatic and precise 3D segmentation of brain tissues.
Philips' (PHG) CT 5300 to Boost Diagnostic Capabilities
by Zacks Equity Research
Philips (PHG) announces its latest innovation, Philips CT 5300, which leverages the power of AI at every stage in CT scanner operation to enhance productivity and diagnostic capabilities.
Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer
by Zacks Equity Research
Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.
Veeva Systems (VEEV) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both segments.
Veradigm (MDRX) to Acquire AI Service Provider ScienceIO
by Zacks Equity Research
Veradigm (MDRX) is set to acquire ScienceIO to benefit its Provider, Payer and Life Sciences businesses, offering highly differentiated and advanced products to its customers.
Cooper Companies (COO) Q1 Earnings Top, '24 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) first-quarter fiscal 2024 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.
Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down
by Zacks Equity Research
Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.
Merit Medical (MMSI) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.
DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
by Zacks Equity Research
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.
Philips' (PHG) New Innovation to Boost Neurovascular Diagnosis
by Zacks Equity Research
Philips (PHG) announces its latest Azurion neuro biplane system, which aims to improve the diagnosis of stroke and major neurovascular diseases. The system is designed for superior patient care.
Patterson Companies (PDCO) Misses on Q3 Earnings, Lowers EPS View
by Zacks Equity Research
Patterson Companies' (PDCO) third-quarter fiscal 2024 results reflect an improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales appear weak.
Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves
by Zacks Equity Research
Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
Masimo (MASI) Q4 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Despite strength in the Hearables category, Masimo's (MASI) overall fourth-quarter results reflect soft performances.
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
GE HealthCare (GEHC), Biofourmis Partner to Boost At-Home Care
by Zacks Equity Research
GE HealthCare (GEHC) collaborates with Biofourmis to facilitate the patient's journey throughout the healthcare system and make the transition from hospital to home care easier.